40. Marker Updates - Ca 125 • Approved marker to test for recurrence • Remains the single most sensitive and specific marker for ovarian cancer to date • Addition of other markers might improve sensitivity and specificity • Longitudinal assessment may also improve sensitivity and specificity
Half of all ovarian cancers are diagnosed in women > 65yo
Stage I: confined to ovary or ovaries IA: unilateral, capsule intact, no tumor on ext surface. No ascites. IB: bilateral, same as above IC: 1 or both ovaries with ruptured capsule, surface tumor, + ascites or + peritoneal washing
Stage II: Pelvic extension IIA: involvement of uterus or fallopian tubes, (-) peritoneal washings IIB: involvement of other pelvic tissues (bladder, sigmoid colon, rectum), (-) peritoneal washings IIC: IIA or IIB with ruptured capsule, surface tumor, + peritoneal washings or ascites
Stage III: Peritoneal implants outside pelvis or + retroperitoneal or inguinal LN IIIA: grossly limited to true pelvis with microscopic seeding of abdom peritoneum IIIB: Implants on abdom peritoneum < or = 2cm diam IIIC: Implants on abdom peritoneum > 2cm or + retroperitoneal or inguinal LN
CA-125 elevated in: Malignant conditions Ovarian CA of various types Cervical CA Fallopian tube CA Endometrial CA Pancreatic CA Colon CA Breast CA Lymphoma Mesothelioma Benign conditions: Endometriosis Uterine fibroids PID Pregnancy Diverticulitis Pancreatitis Liver disease Renal failure Menstruation Appendicitis Inflammatory bowel disease